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ABSTRACT
Objective The aim of this article was to estimate the population prevalence of seven deﬁned ultrasound ﬁndings of
uncertain signiﬁcance (‘markers’) in the second trimester and the associated risk of adverse pregnancy outcomes.
Method A prospective record-linked cohort study of 30 078 pregnant women who had second trimester anomaly
scans between July 2008 and March 2011 in Wales was conducted.
Results The prevalence of markers ranged from 43.7 per 1000 singleton pregnancies for cardiac echogenic foci [95%
conﬁdence interval (CI): 38.8, 51.1] to 0.6 for mild-to-moderate ventriculomegaly (95% CI: 0.3, 1.0). Isolated echogenic
bowel was associated with an increased risk of congenital anomalies [risk ratio (RR) 4.54, 95% CI: 2.12, 9.73] and
preterm birth (RR 2.30, 95% CI: 1.08, 4.90). Isolated pelvicalyceal dilatation was associated with an increased risk of
congenital anomalies (RR 3.82, 95% CI: 2.16, 6.77). Multiple markers were associated with an increased risk of
congenital anomalies (RR 5.00, 95% CI: 1.35, 18.40) and preterm birth (RR 3.38, 95% CI 1.20, 9.53).
Conclusions These data are useful for counselling families and developing clinical guidance and care pathways
following the detection of markers in clinical practice, particularly the need for follow-up scans to monitor placental
function and growth in pregnancies with isolated echogenic bowel, and further investigation for multiple markers.
© 2015 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
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INTRODUCTION
All women in the UK are offered ultrasound screening for
signiﬁcant fetal anomalies in the second trimester of
pregnancy.1 The National Health Service (NHS) Fetal Anomaly
Screening Programme guidance recommends screening for 11
conditions with detection rates above 50% at this scan,
including anencephaly, open spina biﬁda and gastroschisis.2
‘Deﬁned ultrasound ﬁndings of uncertain signiﬁcance’ or
‘normal variants’3 (referred to as ‘markers’ in this article) are
also identiﬁed at this scan; these include echogenic bowel
(EB), renal pelvicalyceal dilatation (PCD) and cardiac
echogenic foci (CEF). Associations between markers and
adverse pregnancy outcomes including intrauterine fetal
death,4 chromosomal abnormalities5 and cystic ﬁbrosis6 have
been reported. However, many studies of markers have been
conducted at specialist centres where a large proportion of
pregnancies were at high-risk of adverse outcomes.7 Because
previous studies have used inconsistent deﬁnitions of markers
or provide limited details of study population characteristics,8
the population prevalence and clinical sequelae of markers in
women at low risk of adverse pregnancy outcomes remain
uncertain. As a result, guidance on the reporting and
management of markers varies both within and between
countries.1–3,9
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We conducted a population-based cohort study of un-
selected pregnant women receiving antenatal care in Wales,
to determine the prevalence of markers and their association
with adverse pregnancy outcomes (congenital abnormalities,
pre-term birth, small for gestational age (SGA) and stillbirth).
MATERIALS AND METHODS
A detailed protocol for this cohort study has been published
elsewhere.10 All pregnant women attending routine antenatal
care in six of seven Health Boards in Wales, capable of giving
informed consent and having their 18 to 20week ultrasound
scan in a Welsh NHS hospital between July 2008 and March
2011, were eligible for inclusion. The majority of women joined
the study during their ﬁrst antenatal appointment with a
healthcare professional. Informed consent was taken to record
the presence of markers and use NHS numbers to link these
data with routinely collected data on pregnancy outcomes.
Ethical approval
Ethical approval for the study was given by the Multicentre
Research Ethics Committee for Wales (reference 08/MRE09/17)
on 16 April 2008.
Deﬁnitions of markers
Data on seven markers (deﬁned in Table 1) were collected
during the 18 to 20week anomaly scan. Practice in Wales at
the time of the study was to report four of the following: EB,
mild-to-moderate ventriculomegaly (VM), PCD and thickened
nuchal fold (NF). Data on three additional markers were
collected speciﬁcally for this study: choroid plexus cysts
(CPC), CEF and short femur (SF). Information on these three
markers was not included on the scan report, and study
participants were not informed of their presence; this was
explained to women when consent was taken.
Training on the study protocol and diagnostic criteria for
each marker was given to all sonographers conducting
antenatal ultrasound scans in the six participating Health
Boards. Their knowledge of protocol requirements for marker
measurement was assessed after training. This assessment
identiﬁed over-reporting of EB, NF and CPC, and incomplete
understanding of calliper placement in the measurement of
VM and the plane of measurement for PCD. Additional
training on these issues was provided within each Health
Board. We also established a quality assurance (QA) panel to
review the ultrasound scan images of reported markers in
the study.
Ultrasound data collection
Data on the seven markers were recorded during the 18 to
20week scan. An additional reporting screen was added to
the electronic information system for radiological data storage
and reporting in Wales (Radiology Information Service 2,
Table 1 Deﬁnitions of markers used in this study and reported prevalence from previous studies
Marker Deﬁnition
Reported prevalence at fetal anomaly
scan from previous studies
Four markers routinely reported in Wales
Echogenic bowel Areas of increased echogenicity in the fetal bowel as bright as bone. Single or multiple
loops of bowel may be identiﬁed, and it may be noted to be solid intraluminal
echogenicity or occasional echogenicity of the walls only (tram line).
2–14 per 10004,18,19
Mild-to-moderate ventriculomegaly Mild-to-moderate ventriculomegaly is a ventricular atrial diameter, at any gestation,
from 10 to 15 mm. Measurements are obtained from a transventricular axial view at
the level of the glomus of the choroid plexus. The callipers were placed on the inner
margins of the echogenic ventricular wall.
1 per 100020
Pelvicalyceal dilatation Fluid ﬁlled dilatation of the renal pelvis measured on axial section with an anterior–
posterior diameter of 5 mm or greater (callipers to be placed on the inner AP margins
of the pelvic wall). This may be unilateral or bilateral.
3–45 per 10004,17
Thickened nuchal fold Thickening of the skin and the subcutaneous tissues on the posterior aspect of the fetal neck.
This is best viewed in a modiﬁed biparietal diameter view to include the cavum septum
pellucidum and cerebellum. Assessed by measuring the distance between the skin and
occipital bone at the posterior aspect of the neck with the callipers placed on the outer
edge of the bone and the outer edge of the skin. A measurement of 6 mm or greater was
considered to indicate thickening before 20 + 6 weeks’ gestation.
1–6 per 100019,21,22
Three additional markers examined in this study
Choroid plexus cysts Small sonographically discrete ﬂuid-ﬁlled spaces ≥5 mm within the choroid plexus and
seen on scan as black echo-free areas. May be single, multiple, unilateral or bilateral.
6–21 per 100019,23
Cardiac echogenic foci Echogenic area on the papillary muscle of either (usually left) or both of the
atrioventricular valves
5–49 per 100019,24,25
Short femur Femur length which is below two standard deviations (3rd percentile) for gestational age
whenmeasuredwith the shaft of the femur parallel to the transducer. Care must be taken to
ensure that the entire diaphysis of the femur is measured. If the epiphyseal cartilages are
visible, they were not included in the measurement. It is assumed that the remainder of the
skeleton is normal.
<50 per 10004
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RadIS2) to enable rapid and accurate data collection by
sonographers while performing the scan. Alternative data
collection arrangements were implemented in three Health
Boards where RadIS2was not yet operational, with sonographers
completing a paper data collection form. At the end of
recruitment, we contacted all Health Boards if scan data were
missing for women who had consented to take part in the study.
Where possible, data for these women were downloaded from
the Health Boards’ reporting systems; data on the four markers
routinely reportedwere available from these reports, but no data
on the additional three markers included in this study could be
obtained from these.
The QA panel conﬁrmed the presence of reported markers
and identiﬁed false positives. A reported marker was conﬁrmed
if the panel agreed by consensus that the marker was present.
They also reviewed scan images for stillbirths and babies with
Down syndrome, Edward’s syndrome and cystic ﬁbrosis to
ascertain whether there were any markers in those scans that
had not been reported at the time of the scan. A review of all
scans to assess for false negatives was not possible because of
the substantial number of scans.
Deﬁnitions of adverse pregnancy outcomes
Congenital anomalies were deﬁned as all abnormalities included
in Chapter XVII of the 10th revision of the International
Statistical Classiﬁcation of Diseases (codes Q00 to Q99),11
including congenital malformations and chromosomal
abnormalities. This is consistent with the deﬁnition used in the
European Surveillance of Congenital Anomalies. Data were
obtained from cytogenetic results following amniocentesis or a
report to the Congenital Anomaly Registry and Information
Service (CARIS) in Wales up to 1 year after the birth. Preterm
birth was deﬁned as a birth before 37weeks’ gestation, and
SGA was deﬁned as below the third centile for birthweight
appropriate for gestational age, stratiﬁed by sex. It was also
speciﬁed a priori that data on stillbirths would be collected and
that this outcome would be examined if there were adequate
numbers. Stillbirths were deﬁned as the in-utero death of a baby
after 24 completed weeks’ gestation.
We used the NHS numbers of study participants to link the
ultrasound scan data with data on the outcomes deﬁned
earlier from the National Community Child Health Database
and CARIS. This extraction was co-ordinated by the NHSWales
Informatics Service. An anonymised dataset for analysis was
produced following linkage to scan data.
Sample size calculation
It was anticipated that approximately 39 000 pregnant women
would be eligible for recruitment. We estimated that if we
achieved a 75% participation rate, and if complete ultrasound
and outcome data were available for 80% of pregnancies, the
ﬁnal sample size would be 23 000. This would allow the
prevalence of a marker with 1.0% prevalence to be estimated
to within 0.1%. Assuming a marker prevalence of 1%, 23 000
pregnancies would also be adequate to detect a ﬁvefold
increase in an adverse pregnancy outcome that had a
prevalence of 1%, or a twofold increase in an outcome with a
prevalence of 5%, with 80% power and a 5% type 1 error rate.
Statistical analysis
Analyses were restricted to singleton pregnancies. We used the
residential postcode to assign each woman into one of the 1896
lower layer super output areas (LSOA) in Wales and hence to a
social deprivation quintile derived using the Welsh Index of
Multiple Deprivation,12 with equal counts of LSOAs in each
quintile. The percentage of women in each deprivation quintile
and the percentage of women with adverse pregnancy
outcomes were compared between women with and without
scan data, and with published data for all pregnant women in
Wales, to assess how representative the study sample was of
the general population.
Calculation of marker prevalence
The prevalence of conﬁrmed markers per 1000 singleton
pregnancies in the population and 95% conﬁdence intervals
(CI) were estimated using bootstrappingwith 5000 replications,13
to account for additional uncertainty, ﬁrst, because not all scan
images in which a marker had been identiﬁed were available
for review and second, because those scans that were reviewed
provided an estimate of the false negative rate.
Association between markers and pregnancy outcomes
Unadjusted risk ratios with 95% CI were calculated using Stata
version 13.0 (StataCorp. 2013. Stata: Release 13. Statistical
Software. College Station, TX: StataCorp LP), estimating the risk
of the adverse pregnancy outcomes in pregnancies wheremarkers
had been identiﬁed compared with pregnancies in which there
were no markers. We performed separate analyses for isolated
markers and pregnancies in which multiple markers had been
identiﬁed because previous research has suggested an increased
risk of adverse outcomes with multiple markers. This analysis
included only conﬁrmed markers and was therefore restricted to
the study population for whom data were available on all seven
markers. Due to small numbers of pregnancies with markers and
adverse pregnancy outcomes, we could not stratify our analyses
for other factors (such as gestational age or maternal age).
RESULTS
Study sample
Of the 33252 women approached to take part, 90.5% (n= 30 078)
consented. Of these, 29 695 had singleton pregnancies. Figure 1
shows the ﬂow of participants through the study. Data from
22045 scans were accessed. The prevalence of the four markers
routinely reported in Wales was calculated using data from
21761 scans (284 excluded because the images were not
available for review by the QA panel). The prevalence of the
three additional markers was estimated using 18 841 scans
(excluding 2920 that had been obtained from the routine
reporting systems of the Health Boards, which did not contain
information on these additional markers). The estimates for
the risk ratios were based on 18 339 scans (502 excluded as no
data on adverse pregnancy outcomes were accessible for these).
Characteristics of study women
Table 2 shows the characteristics and pregnancy outcomes of
women with scan data (n=22045), without scan data (n=7,651)
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and population data for Wales from published sources.14–16 The
characteristics and pregnancy outcomes in the three populations
were similar. Almost 85% of women with scan data were younger
than 35years of age, and 27% were classiﬁed as living in the most
deprived quintile. There were 81 stillbirths in the 22045
pregnancies with scan data (0.4%), 587 congenital anomalies
(2.7%) and 1142 babies born before 37weeks of gestation (5.4%).
A higher percentage of women without scan data experienced
an induced or spontaneous pregnancy loss; the timing of these
lost pregnancies was not known but may explain why scan data
were missing for some of these women.
Prevalence of markers
Table 3 shows the number and prevalence of reported
markers, the prevalence range across Heath Boards, the
numbers included in the QA review and the number and
prevalence of conﬁrmed markers. During the study, 1583
markers were reported; 369 of the four markers routinely
reported in practice and 1214 of the three additional markers.
We obtained scan images for 1295 of these for review by the
QA panel; 328 (88.9%) for the markers routinely reported, and
967 (79.7%) for the other markers. Overall, one in ﬁve of the
reported markers were not conﬁrmed when the scan images
were reviewed by the QA panel. The panel conﬁrmed 242
(73.8%) of the four markers routinely reported and 784
(81.1%) of the other three markers. In addition, the QA process
identiﬁed eight unreported markers (one EB, one NF, two CEF
and one CPC from the review of scans with reported markers
and one EB, one NF and one CEF from the images of
stillbirths). No additional markers were found in the scans for
babies with Down or Edward’s syndrome or cystic ﬁbrosis.
The estimated prevalence of markers per 1000 singleton
pregnancies (from commonest to rarest) was 43.7 for CEF (95%
CI 38.8, 51.1); 12.1 for CPC (95% CI 10.1, 15.0); 7.6 for PCD (95%
CI 6.5, 8.8); 4.2 for EB (95% CI 2.7, 7.0); 2.9 for NF (95% CI 1.2,
5.5); 0.8 for SF (95% CI 0.4, 1.3); and 0.6 for VM (95% CI 0.3, 1.0).
Association between markers and pregnancy outcome
Figure 2 shows the number of adverse pregnancy outcomes in
pregnancies with isolated markers, multiple markers and no
Figure 1 Cohort ﬂow chart
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markers. The number of pregnancies with a conﬁrmed marker
and an adverse pregnancy outcome is small. For example, of
the 50 pregnancies with an isolated EB, therewere two stillbirths,
six congenital abnormalities, six preterm deliveries and three
babies with SGA. In this cohort, there were 17 pregnancies that
had two markers (both conﬁrmed by the QA panel).
In the 47 pregnancies with markers and congenital anomalies
identiﬁed, there were ﬁve chromosomal abnormalities: one
infant with CPC had Trisomy 18; three infants with CEF had
Trisomy 21; and one infant with CPC had Trisomy 21.
Table 4 shows the risk ratios for the association of isolated
markers with congenital anomalies, preterm birth and SGA
for the markers, which were identiﬁed in adequate numbers
(at least 50). EB was associated with an increased risk of
congenital anomalies (unadjusted risk ratio [RR] 4.54, 95% CI:
2.12, 9.73) and preterm birth (RR 2.30, 95% CI: 1.08, 4.90).
PCD was associated with an increased risk of congenital
anomaly (RR 3.82, 95% CI: 2.16, 6.77); nine of these were
anomalies of the kidneys or urinary tract. CEF were associated
with an increased risk of preterm birth (RR 1.36, 95% CI: 1.01,
1.84), although the size of this association was smaller than
those seen with other markers. The association between
multiple markers and adverse outcomes was expected to be
stronger, allowing the calculation of risk ratios based on a
small number of cases. Multiple markers were associated with
an increased risk of congenital anomalies (RR 5.00, 95% CI 1.35,
18.40) and preterm birth (RR 3.38, 95% CI 1.20, 9.53).
Very few pregnancies with markers ended in a stillbirth and
estimating a reliable risk ratio was not possible for most
markers. EB was associated with an increased risk of stillbirth
(RR 12.19, 95% CI: 3.06, 48.63), although this estimate should
be interpreted with caution: of the two cases of EB on which
the estimate is based, one was identiﬁed when the QA panel
reviewed the scan of a baby that was stillborn.
DISCUSSION
In our population-based study of non-selected pregnant
women, the prevalence of markers ranged from 43.7 per 1000
pregnancies for CEF to 0.6 per 1000 pregnancies for VM. One
in ﬁve of the markers originally reported was not conﬁrmed
when the scan images were reviewed by a QA panel. EB and
multiple markers were associated with an increased risk of
congenital anomalies and preterm birth. PCD was associated
with an increased risk of congenital anomalies.
This was a large study of women attending obstetric care,
who were representative of pregnant women in Wales, and
provides population-based estimates for the prevalence of
markers in the general obstetric population using data
collected prior to referral to specialist fetal-medicine centres.
Recruitment and ultrasound data collection were embedded
within the routine healthcare system, and 90.5% of women
who were approached agreed to take part. The stringent QA
process was a strength of the study, with scan images reviewed
by an expert panel to conﬁrm the presence of markers and
ensure ﬁdelity with the study protocol.
Scan data were only available for 74% of women who had
consented to take part. This was most likely because we relied
on sonographers to identify enrolled women when they
attended for their scan and to access the data collection screen
or complete the paper form during the scan appointment. In
cases where the sonographer did not do this, we were able to
access some of the missing data from the reporting system in
Health Boards, although we were only able to obtain data on
the four routinely reported markers using this method. The
distributions of maternal age, social deprivation and pregnancy
outcomes in women with and without scan data were similar.
They were also comparable with routinely-available estimates
suggesting that, although these data collectionmethods reduced
our sample size, the resulting study sample was representative
of the general obstetric population in Wales.
Previous reports of the prevalence of markers at 18 to
20week scans vary.4,17–25 Our prevalence estimates are
consistent with the lower end of published ranges. It is of
concern that one in ﬁve of the markers originally reported in
the study was classed as false positives after QA review. This
Table 2 Characteristics and pregnancy outcomes of singleton
pregnancies with scan data, eligible pregnancies without scan
data and population data from published sources for Wales
Characteristic
Pregnancies
with scan
data
Pregnancies
with no scan
data
Population data
from published
sourcesg
N (%a) N (%a) %
Maternal ageb
<35 18 676 (84.7) 6319 (82.6) 84.2
35+ 3369 (15.3) 1327 (17.4) 15.8
Deprivation quintilec
1 (least deprived) 3237 (16.4) 845 (13.0) 15.1
2 3249 (16.4) 1157 (17.8) 17.4
3 3773 (19.1) 1444 (22.2) 19.7
4 4223 (21.4) 1498 (23.1) 22.4
5 (most deprived) 5287 (26.7) 1550 (23.9) 25.5
Pregnancy outcomed
Live birth 21 308 (99.4) 6247 (94.3) 99.6
Stillbirth 81 (0.4) 20 (0.3) 0.4
Induced or
spontaneous
pregnancy loss
48 (0.2) 358 (5.4)
Congenital
abnormalitiese
587 (2.7) 258 (3.4) 3.3
Premature delivery
(<37 weeks)f
1142 (5.4) 325 (5.2) 5.7
aPercentages calculated for pregnancies with available data.
bN = 22 045 (100%) for pregnancies with scan data and 7646 (99.9%) for
pregnancies without scan data.
cN = 19 769 (89.7%) for pregnancies with scan data, and 6494 (84.9%) for
pregnancies without scan data.
dN = 21 437 (97.2%) for pregnancies with scan data and 6625 (86.6%) for
pregnancies without scan data.
eCalculated as a percentage of live births, stillbirths and pregnancy losses.
fCalculated as a percentage of live births.
gData on maternal age (includes multiple pregnancies), social deprivation quintile,
pregnancy outcomes and stillbirths (singleton pregnancies only) from the All Wales
Perinatal Survey 201213; data on major congenital anomalies from CARIS 201214;
and data on premature deliveries from the Ofﬁce for National Statistics website
information for England and Wales 201215.
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ﬁnding is important, as reporting the presence of markers to
parents may cause signiﬁcant anxiety and can lead to the
uptake of unnecessary invasive procedures.17
There was inter-sonographer variability in reporting, despite
clear study deﬁnitions and training at the start of the study.
Variation in the reporting of markers within studies has been
shown previously for PCD26 and VM.27 Differences between
Health Boards were smaller for the markers routinely reported
in Wales (for example, the range for EB was 2.6 to 5.3 per 1000)
compared with the additional markers included in this study
(for example, the range for CEF was 18.5 to 73.7 per 1000),
suggesting that sonographer experience may play an
important role in reporting accuracy. Audit of screening
activity, continuous monitoring and feedback of screening
programme parameters (including true and false positive and
negative rates) should be essential activities within antenatal
screening programmes using ultrasound. Evidence in the UK,
however, suggests that 80% of units screening for fetal
anomalies are unable to provide detection rates for various
abnormalities.28 This highlights the need for appropriate
training, re-training and QA procedures if these markers
continue to be routinely identiﬁed at antenatal screening.
Figure 2 Number of conﬁrmed isolated markers and multiple markers, and pregnancy outcomes by marker status, in singleton study
pregnancies where scan data were available for all seven markers
Table 3 Number and prevalence per 1000 singleton pregnancies of reported markers, number in quality assurance review and
estimated prevalence (per 1000 singleton pregnancies) and 95% CIs for each marker
Number of
reported
markersa
Prevalence
per 1000
singleton
pregnancies
Range of
prevalence
across Health
Boards
Number (%)
in quality
assurance
review
Number (%)
conﬁrmed
False
negatives
identiﬁed
during
quality
assurance
Number of
conﬁrmed
markers
Estimated
prevalence per
1000 singleton
pregnancies
(95% CI)
Four markers routinely reported in Wales
Echogenic bowel 83 3.8 2.6–5.3 78 (94.0) 55 (70.5) 2 57 4.2 (2.7, 7.0)
Mild-to-moderate
ventriculomegaly
23 1.0 0.4–1.8 20 (87.0) 11 (55.0) 0 11 0.6 (0.3, 1.0)
Mild pelvicalyceal
dilatation
221 10.0 6.6–15.9 189 (85.5) 144 (76.2) 0 144 7.6 (6.5, 8.8)
Thickened nuchal fold 42 1.9 0.2–5.1 41 (97.6) 32 (78.0) 2 34 2.9 (1.2, 5.5)
Three additional markers examined in this study
Choroid plexus cysts 330 17.3 9.9–21.8 242 (73.3) 158 (65.3) 1 159 12.1 (10.1, 15.0)
Cardiac echogenic foci 858 44.9 18.5–73.7 702 (81.8) 612 (87.2) 3 615 43.7 (38.8, 51.1)
Short femur 26 1.4 0.2–3.0 23 (88.5) 14 (60.9) 0 14 0.8 (0.4, 1.3)
CI, conﬁdence interval.
aAll markers, whether isolated or not
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Much of the previous literature had focused on the role that
markers play in screening for aneuploidy. A recent meta-
analysis showed that the prevalence of markers at the second
trimester scan is higher in infants with trisomy 21 than in
euploid infants; however, for most isolated markers,
information collected at the second trimester scan made only
a small difference to the risk estimate already calculated using
other screening methods (maternal age, second trimester
serum biochemical testing or ﬁrst trimester combined
testing).29 Other reviews have supported this conclusion,
suggesting that ﬁrst trimester screening has dramatically
decreased the prevalence of Down syndrome identiﬁed in the
second trimester (as seen in our data)30 and that second
trimester scans are now of most use for screening in settings
when access to genetic testing is limited, when serum
screening tests give inconclusive results or as ‘a noninvasive
supplementary test for high-risk women reluctant to undergo
invasive diagnostic screening’.31
Previous studies have suggested associations between EB
and other adverse pregnancy outcomes. Gestational age at
birth has been shown to be signiﬁcantly lower,32 and an
increased risk of SGA and intrauterine fetal death4,32 has been
seen in pregnancies where EB has been identiﬁed. Some of
our results were consistent with these ﬁndings, in that we
showed an increase in preterm births and stillbirths (although
our numbers for this outcome are small). Differences between
our results and these studies could be explained by different
deﬁnitions and different populations under study. For
example, Goetzinger et al.4 used birthweight <10th percentile
for gestational age to identify babies with SGA, whereas we
used a more restricted deﬁnition of birthweight <3rd
percentile; both previous studies included intrauterine deaths
from 20weeks onwards, whereas we included deaths from
24weeks, and Mailath-Pokorny et al.32 used data from fetal
medicine centres with higher rates of adverse pregnancy
outcomes compared with the general population. Goetzinger
et al.4 also adjusted their results for multiple potential
confounders, but this did not change the magnitude of the
associations seen suggesting that similar multivariate analyses
may not have changed the conclusions of our analyses. The
mechanism for the association between EB and these adverse
pregnancy outcomes is unclear, but may involve vascular
disruption leading to bowel hypo-perfusion and ischaemia.4
Stillbirth, preterm birth and SGA have a multifactorial
aetiology. Despite our large sample size, we were not able to
account for these complexities in our analysis because of low
prevalence of markers and adverse pregnancy outcomes.
Nevertheless, taken together, the ﬁndings from these three
studies indicate the need for monitoring pregnancies for
growth and placental function following the detection of EB
in the second trimester of pregnancy. Our data are also
consistent with the ﬁnding that the risk of adverse outcomes
is higher when two or more markers are identiﬁed8 and
support guidance that additional investigation and follow-up
is required for these pregnancies.1
Associations with adverse outcomes have also been reported
for markers other than EB, although information is sparse for
some markers and for the long-term implications for health
during childhood. For example, a systematic review of
outcomes associated with VM found that the risk of
neurological abnormality diagnosed after birth was 12% to
14% (depending on the presence of infection or chromosomal
abnormalities)33; mild pyelectasis was not associated with an
increased risk of urinary tract infection during childhood in a
case–control study in the Netherlands34; and a study in Brazil
reported that 2.7% of infants with cardiac echogenic focus
had cardiac anomalies, 3.7% had chromosomal abnormalities
and 1.7% had cardiac defects.35 Further studies examining
the association between speciﬁc markers and longer-term
adverse health outcomes in childhood are needed, to examine
whether the associations seen in our study have implications
for later health.
CONCLUSION
In this study, markers were identiﬁed in more than 50 in 1000
singleton pregnancies, and associations between some markers
and adverse pregnancy outcomes were seen. Our data are useful
for counselling families and developing clinical guidance and
care pathways following the detection of markers in clinical
practice, particularly for isolated EB, and further investigation
for multiple markers. Further work clarifying the implications
of markers for health outcomes during childhood is needed.
Table 4 Unadjusted risk ratios (95% CI) for adverse pregnancy outcomes in pregnancies with conﬁrmed markers compared with
pregnancies with no conﬁrmed markers
Congenital abnormalitiesa Preterm birthsb SGAb
Echogenic bowel 4.54 (2.12, 9.73)c 2.30 (1.08, 4.90) 1.89 (0.63, 5.67)
Mild pelvicalyceal dilatation 3.82 (2.16, 6.77)d 0.71 (0.27, 1.85) 1.36 (0.57, 3.21)
Choroid plexus cysts 1.44 (0.61, 3.43) 1.23 (0.65, 2.32) 0.45 (0.11, 1.80)
Cardiac echogenic foci 1.33 (0.84, 2.08) 1.36 (1.01, 1.84) 0.84 (0.52, 1.38)
CI, conﬁdence interval; SGA, small for gestational age.
aDenominator = live births, stillbirths and pregnancy losses.
bDenominator = live births only.
cThe abnormalities in the six babies with echogenic bowel were cystic ﬁbrosis, gastroschisis, jejunal atresia, pulmonary hypoplasia, double outlet right ventricle and congenital
cytomegalovirus infection.
dNine of the eleven babies with mild pelvicalyceal dilatation were diagnosed with a renal abnormality after birth; in the other two, the diagnoses were right intra-lobar
sequestration of lung and discordant great arteries (Taussig–Bing anomaly).
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WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• The prevalence and clinical sequelae of deﬁned ultrasound ﬁndings
of unknown signiﬁcance (‘markers’) in pregnant women at low risk
of adverse pregnancy outcomes are uncertain.
• Guidance on the reporting and clinical management of markers
varies between and within countries.
WHAT DOES THIS STUDY ADDS?
• This study provides population-based estimates for the prevalence of
markers in the general obstetric population, using data collected
prior to referral to specialist fetal-medicine centres.
• There is inter-sonographer variation in the reporting of markers,
suggesting that continuous quality assurance programmes are
essential within antenatal ultrasound screening services.
• Isolated echogenic bowel and multiple markers are associated with
an increased risk of congenital anomalies and preterm births, and
isolated pelvicalyceal dilatation is associated with an increased risk
of congenital anomalies.
• These datawill be useful in counselling families and in the development
of clinical guidelines and care pathways for the management of
markers detected in the second trimester of pregnancy.
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